We are monitoring the impact of COVID-19 & Recession alarm on Europe Neurotherapeutics Market Get in touch with us for detailed analysis Know More
Share on

Europe Neurotherapeutics Market Research Report – Segmented By Treatment, Disorders, Distribution Channels & Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) – Industry Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 1198
Pages: 132

The size of the European Neurotherapeutics Market is projected to be rising at a prominent rate between 2022 to 2027. Europe has the second-highest share in the market due to increasing awareness among people over various neurological conditions.

Growing number of people affected by chronic pain, neurological disorders such as epilepsy, brain aneurysm and brain tumor etc. along with public awareness and availability of several neurotherapeutics drugs or devices will drive the Europe neurotherapeutics market growth. According to the World Health Organization (WHO), around 3.69 million people suffer from epilepsy and more than 155,000 new cases are diagnosed each year, which is expected to lead to the adoption of neurotherapeutics devices. Additionally, clinical evidence for neurostimulation devices is likely to increase over drug therapies, both of which constitute to the Europe neurotherapeutics market over the expected time. Atleast 1 in 69 British men and 1 in 65.6 British women will be diagnosed with a brain or central nervous system or intracranial tumor in their lifetime. 3.54% of brain and central nervous system tumors reported in the UK region are preventable. In 2018, approximately 3,100 women and 3,940 men in Germany were diagnosed with malignant CNS tumor.

The prevalence of Parkinson's disease has been on a steady rise over the past several years in Europe. This is mainly due to the increase in the geriatric population who are more neurological diseases. According to the 2018 United Nations Population Aging Report, the population aged 60 and over represents 25% of the UK population and is estimated to reach 32% by 2050 according to the report's estimates. Each year, more than 55,000 Europeans are diagnosed with Parkinson's disease. As a result, the diagnosis and treatment options for neurotherapeutics devices are expected to increase in the future. This will increase the demand for new and better innovative products, thereby helping the market to grow in the future. Additionally, technologically advanced systems can be recharged wirelessly without the need for additional surgeries, especially for deep brain stimulation systems.

However, the major factors hampering the growth of the Europe neurotherapeutics market include side effects such as allergic reactions, stinging or itching of the skin due to the implantation of devices or drugs. Additionally, neurotherapeutics devices are costly, which may hamper the market during the studied market.

This research report on the European neurotherapeutics market has been segmented and sub-segmented into the following categories.

By Treatment:

  • Neurologic drugs
    • Oral administration
    • Injections
  • Neurologic devices
    • Electroconvulsive Therapy (ECT)
    • Vagus Nerve Stimulation (VNS)
    • Transcranial magnetic stimulation
    • Deep Brain Stimulator

By Disorders:

  • Central Nervous System (CNS) Disorders
  • Peripheral Nervous System (PNS) Disorders
  • Autonomous Nervous System (ANS) Disorders

By Distribution channels:

  • Hospitals
  • Neurotherapeutic Centre
  • Clinical research organizations
  • Clinics

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Geographically, Germany is anticipated to grow at the highest CAGR in this region over the forecast period. This market is growing with increasing prevalence of depression in adolescents, large neurotherapeutics key markets, developed healthcare sectors, growing awareness and research and development activities. According to Barmer, a German health insurance company, around 470,500 German students suffered from mental disorders. And, currently more than 1.58 million people live with Alzheimer's disease. This has led to the growth in healthcare expenditure for the treatment of such diseases and which provides lucrative opportunities to drive the growth of the neurotherapeutics market in Germany.

In Europe, the United Kingdom had largest market share in 2020, owing to favourable reimbursement polices and high incidences of CNS diseases in the region. At least 6.65 million people suffer from epilepsy and 15.6 million Europeans will have a seizure at some point in their life. However, in some European countries, up to 41% of people suffering from epilepsy do not receive treatment as it is not considered as a brain disorder. While in UK, the incidence is estimated around 51 per 100,000 per year, the cases of active epilepsy was estimated over 10 cases per 1000. Two-thirds of people with active epilepsy have their success with antiepileptic drugs (EAF).

Meanwhile Spain is projected to have steady growth rate during the analysis period, attributed to the increase in demand for neurostimulation devices and demand for good quality healthcare. This nation is making efforts to improve the overall quality of life of patients, thus promoting the adoption of neurotherapeutics in the country. Moreover, the reimbursements of neurostimulation devices and increased public awareness is also driving the market growth.

KEY MARKET PLAYERS:

Some of the major players in Europe Neurotherapeutics Market are Abbott Laboratories, Inc., Becton, Novartis AG, Dickinson and Company, Pfizer, Inc., Johnson & Johnson, Biogen, Inc., GlaxoSmithKline, Inc., AstraZeneca plc, Sanofi-Aventis, Spiegelberg, stryker, Covidien, Medtronic, GE healthcare, and Merck & Co.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Treatment                  

                                5.1.1 Introduction           

                                5.1.2 Neurologic Drugs 

                                                5.1.2.1 Oral Administration

                                                5.1.2.2 Injections

                                                5.1.2.3 Others

                                5.1.3 Neurologic Devices             

                                                5.1.3.1 Electroconvulsive Therapy (ECT)

                                                5.1.3.2 Vagus Nerve Stimulation (VNS)

                                                5.1.3.3 Transcranial magnetic stimulation

                                                5.1.3.4 Deep Brain Stimulator

                                                5.1.3.5 Others

                                5.1.4 Y-o-Y Growth Analysis, By Product

                                5.1.5 Market Attractiveness Analysis, By Product               

                                5.1.6 Market Share Analysis, By Product                

                5.2 Disorders                    

                                5.2.1 Introduction           

                                5.2.2 Central Nervous system disorder  

                                5.2.3 Peripheral Nervous system disorder            

                                5.2.4 Autonomous Nervous system disorder       

                                5.2.5 Y-o-Y Growth Analysis, By Type      

                                5.2.6 Market Attractiveness Analysis, By Type     

                                5.2.7 Market Share Analysis, By Type      

                5.3 Distribution Channels                            

                                5.3.1 Introduction           

                                5.3.2 Hospitals  

                                5.3.3 Neurotherapeutic center  

                                5.3.4 Clinical Research organisations      

                                5.3.5 Clinics        

                                5.3.6 Y-o-Y Growth Analysis, By Application         

                                5.3.7 Market Attractiveness Analysis, By Application        

                                5.3.8 Market Share Analysis, By Application         

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Treatment

                                                6.1.3.3 By Disorders

                                                6.1.3.4 By Distribution Channels

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Treatment

                                                6.1.4.3 By Disorders

                                                6.1.4.4 By Distributional Channels

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Treatment

                                                6.1.5.3 By Disorders

                                                6.1.5.4 By Distribution channels

                6.2 U.K                

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 Abbott Laboratories               

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Becton                         

                8.3 Novartis AG                

                8.4 Dickinson and Company                       

                8.5 Pfizer                            

                8.6 Johnson & Johnson                 

                8.7 Biogen                          

                8.8 Glaxosmithkline                       

                8.9 AstraZeneca               

                8.10 Sanofi Aventis                        

                8.11 Spiegelberg                             

                8.12 Covidien                    

                8.13 Medtronic                

                8.14 GE Health Care                       

                8.15 Merck & Co                              

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. Europe Neurotherapeutics Market, By Treatment, From 2022 - 2027 (USD Billion)
  2. Europe Neurologic Drugs Market, By Region, From 2022 - 2027 (USD Billion)
  3. Europe Neurologic Devices Market, By Region, From 2022 - 2027 (USD Billion)
  4. Europe Neurotherapeutics Market, By Disorders, From 2022 - 2027 (USD Billion)
  5. Europe Central Nervous system disorders Market, By Region, From 2022 - 2027 (USD Billion)
  6. Europe Peripheral Nervous system disorders Market, By Region, From 2022 - 2027 (USD Billion)
  7. Europe Autonomous Nervous system disorders Market, By Region, From 2022 - 2027 (USD Billion)
  8. Europe Neurotherapeutics Market, By Distribution Channels, From 2022 - 2027 (USD Billion)
  9. Europe Hospitals Market, By Region, From 2022 - 2027 (USD Billion)
  10. Europe Neurotherapeutic center Market, By Region, From 2022 - 2027 (USD Billion)
  11. Europe Clinical research organisations Market, By Region, From 2022 - 2027 (USD Billion)
  12. Europe clinics Market, By Region, From 2022 - 2027 (USD Billion)
  13. U.K. Neurotherapeutics Market, By Treatment, From 2022 - 2027 (USD Billion)
  14. U.K. Neurotherapeutics Market, By Disorders, From 2022 - 2027 (USD Billion)
  15. U.K. Neurotherapeutics Market, By Distribution Channels, From 2022 - 2027 (USD Billion)
  16. Germany Neurotherapeutics Market, By Treatment, From 2022 - 2027 (USD Billion)
  17. Germany Neurotherapeutics Market, By Disorders, From 2022 - 2027 (USD Billion)
  18. Germany Neurotherapeutics Market, By Distribution Channels, From 2022 - 2027 (USD Billion)
  19. France Neurotherapeutics Market, By Treatment, From 2022 - 2027 (USD Billion)
  20. France Neurotherapeutics Market, By Disorders, From 2022 - 2027 (USD Billion)
  21. France Neurotherapeutics Market, By Distribution Channels, From 2022 - 2027 (USD Billion)
  22. Italy Neurotherapeutics Market, By Treatment, From 2022 - 2027 (USD Billion)
  23. Italy Neurotherapeutics Market, By Disorders, From 2022 - 2027 (USD Billion)
  24. Italy Neurotherapeutics Market, By Distribution Channels, From 2022 - 2027 (USD Billion)
  25. Spain Neurotherapeutics Market, By Treatment, From 2022 - 2027 (USD Billion)
  26. Spain Neurotherapeutics Market, By Disorders, From 2022 - 2027 (USD Billion)
  27. Spain Neurotherapeutics Market, By Distribution Channels, From 2022 - 2027 (USD Billion)
  28. Europe Neurotherapeutics Market, By Neurologic drugs, From 2022 - 2027 (USD Billion)
  29. Europe Oral Administrations Market, By Region, From 2022 - 2027 (USD Billion)
  30. Europe Injections Market, By Region, From 2022 - 2027 (USD Billion)
  31. U.K. Neurotherapeutics Market, By Neurologic drugs, From 2022 - 2027 (USD Billion)
  32. Germany Neurotherapeutics Market, By Neurologic drugs, From 2022 - 2027 (USD Billion)
  33. France Neurotherapeutics Market, By Neurologic drugs, From 2022 - 2027 (USD Billion)
  34. Italy Neurotherapeutics Market, By Neurologic drugs, From 2022 - 2027 (USD Billion)
  35. Spain Neurotherapeutics Market, By Neurologic drugs, From 2022 - 2027 (USD Billion)
  36. Europe Neurotherapeutics Market, By Neurologic devices, From 2022 - 2027 (USD Billion)
  37. Europe Electroconvulsive Therapy (ECT) Market, By Region, From 2022 - 2027 (USD Billion)
  38. Europe Vagus Nerve Stimulation (VNS) Market, By Region, From 2022 - 2027 (USD Billion)
  39. Europe Transcranial magnetic stimulation Market, By Region, From 2022 - 2027 (USD Billion)
  40. Europe Deep Brain Stimulator Market, By Region, From 2022 - 2027 (USD Billion)
  41. U.K. Neurotherapeutics Market, By Neurologic devices, From 2022 - 2027 (USD Billion)
  42. Germany Neurotherapeutics Market, By Neurologic devices, From 2022 - 2027 (USD Billion)
  43. France Neurotherapeutics Market, By Neurologic devices, From 2022 - 2027 (USD Billion)
  44. Italy Neurotherapeutics Market, By Neurologic devices, From 2022 - 2027 (USD Billion)
  45. Spain Neurotherapeutics Market, By Neurologic devices, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample